NovoCure Limited
General ticker "NVCR" information:
- Sector: Health Care
- Industry: Health Care Equipment & Supplies
- Capitalization: $2.0B (TTM average)
NovoCure Limited does not follow the US Stock Market performance with the rate: -6.2%.
Estimated limits based on current volatility of 4.2%: low 11.08$, high 12.05$
Factors to consider:
- Total employees count: 1488 (+2.4%) as of 2024
- US accounted for 64.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Dependence on key products, Regulatory and compliance, Expansion risks, Market acceptance of new products, Market competition
- Current price 21.4% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [14.96$, 35.17$]
- 2025-12-31 to 2026-12-31 estimated range: [12.82$, 30.75$]
Financial Metrics affecting the NVCR estimates:
- Negative: with PPE of -19.7 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -0.80 <= 0.33
- Positive: -8.75 < Industry operating profit margin (median), % of -7.19
- Positive: Inventory ratio change, % of -0.80 <= -0.75
- Positive: -4.48 < Investing cash flow per share per price, % of -4.23
Short-term NVCR quotes
Long-term NVCR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $537.84MM | $509.34MM | $605.22MM |
| Operating Expenses | $627.36MM | $742.21MM | $775.72MM |
| Operating Income | $-89.52MM | $-232.87MM | $-170.50MM |
| Non-Operating Income | $7.68MM | $41.13MM | $39.33MM |
| R&D Expense | $206.09MM | $223.06MM | $209.65MM |
| Income(Loss) | $-81.85MM | $-191.74MM | $-131.16MM |
| Taxes | $10.69MM | $15.30MM | $37.47MM |
| Profit(Loss)* | $-92.53MM | $-207.04MM | $-168.63MM |
| Stockholders Equity | $441.17MM | $362.50MM | $360.18MM |
| Inventory | $29.38MM | $38.15MM | $35.09MM |
| Assets | $1,191.65MM | $1,146.13MM | $1,240.78MM |
| Operating Cash Flow | $30.79MM | $-73.34MM | $-26.37MM |
| Capital expenditure | $21.36MM | $27.09MM | $42.85MM |
| Investing Cash Flow | $-139.96MM | $184.15MM | $-140.24MM |
| Financing Cash Flow | $15.49MM | $15.79MM | $90.31MM |
| Earnings Per Share** | $-0.88 | $-1.95 | $-1.56 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.